Association between Apolipoprotein A1 (APOA1) Single-nucleotide Polymorphisms and Schizophrenia in a Korean Population

다국어 초록 (Multilingual Abstract)

Objective: Apolipoprotein A1 (APOA1), the major apolipoprotein of high-density lipoproteins, participates in the local transport of lipids used in myelin biosynthesis. Variation in the APOA1 gene may influence protein functioning and consequently myelin biosynthesis in the brain, leading to an increased risk for schizophrenia.
Methods: We used a polymerase chain reaction-based restriction fragment length polymorphism method to determine the association of polymorphisms rs670 and rs5070 with schizophrenia in 185 Korean patients who had the disease and 179 healthy Korean control subjects.
Results: Patients and controls differed significantly in terms of the genotype distributions of the G/A polymorphism (rs5070)(p=0.0102). However, we found no significant differences between patients with schizophrenia and controls in terms of the rs670polymorphism.
Conclusion: Additional studies with larger samples drawn from different populations may be required to determine whether APOA1polymorphisms could be used as markers for susceptibility to schizophrenia. This study is the first to analyze the association between the single-nucleotide polymorphisms of APOA1 and schizophrenia, and the findings may contribute to further studies on the role of APOA1 in schizophrenia.

참고문헌 (Reference)

1 Wang XL, "The effect on transcription efficiency of the apolipoprotein AI gene of DNA variants at the 5' untranslated region" 28 : 235-241, 1998

2 SoléX, "SNPStats: a web tool for the analysis of association studies" 22 : 1928-1929, 2006

3 Talmud PJ, "Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study" 11 : 265-280, 1994

4 Wessman J, "Mixture model clustering of phenotype features reveals evidence for association of DTNBP1 to a specific subtype of schizophrenia" 66 : 990-996, 2009

5 Huang JT, "Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues" 13 : 1118-1128, 2008

6 Kamboh MI, "Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDLcholesterol" 127 : 255-262, 1996

7 Gurling HM, "Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23" 68 : 661-673, 2001

8 La YJ, "Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients" 114 : 657-663, 2007

9 Ma YQ, "Association of two apolipoprotein A-I gene MspI polymorphisms with lipid and blood pressure levels" 102 : 309-314, 2005

10 Chen ES, "Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity" 9 : 319-325, 2009

11 Boyles JK, "Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I" 265 : 17805-17815, 1990

12 Vollbach H, "APOA1 polymorphism influences risk for early-onset nonfamiliar AD" 58 : 436-441, 2005

13 Chen JM, "A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: general principles and overview" 120 : 1-21, 2006

14 Stephens M, "A new statistical method for haplotype reconstruction from population data" 68 : 978-989, 2001